Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

Shane R Stecklein,Miguel Martín,Guillermo Villacampa,María Del Monte-Millan,Rachel Yoder,Harsh Pathak,Sandra Cobo,Fara Brasó-Maristany,Enrique L Álvarez,Isabel Echavarría,Coralia Bueno-Muiño,Yolanda Jerez,María Cebollero,Oscar Bueno,José Á García-Saenz,Fernando Moreno,Henry L Gómez,Tatiana Massarrah,Blanca Herrero,Laia Paré,Mercedes Marín-Aguilera,Wesley Buckingham,Sara López-Tarruella,Patricia Villagrasa,Andrew K Godwin,Roberto Salgado,Aleix Prat,Priyanka Sharma
{"title":"Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.","authors":"Shane R Stecklein,Miguel Martín,Guillermo Villacampa,María Del Monte-Millan,Rachel Yoder,Harsh Pathak,Sandra Cobo,Fara Brasó-Maristany,Enrique L Álvarez,Isabel Echavarría,Coralia Bueno-Muiño,Yolanda Jerez,María Cebollero,Oscar Bueno,José Á García-Saenz,Fernando Moreno,Henry L Gómez,Tatiana Massarrah,Blanca Herrero,Laia Paré,Mercedes Marín-Aguilera,Wesley Buckingham,Sara López-Tarruella,Patricia Villagrasa,Andrew K Godwin,Roberto Salgado,Aleix Prat,Priyanka Sharma","doi":"10.1093/jnci/djaf162","DOIUrl":null,"url":null,"abstract":"Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these two biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"68 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnci/djaf162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these two biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.
基质肿瘤浸润淋巴细胞和TNBC-DX为三阴性乳腺癌的预后提供了补充信息。
三阴性乳腺癌(TNBC)患者在新辅助全身治疗中达到病理完全缓解(pCR)的患者生存率较高,而残留病变患者复发风险较高。基质肿瘤浸润淋巴细胞(sTILs)和TNBC- dx均可预测TNBC的pCR。这两种生物标志物是否提供了互补的信息还没有经过测试。我们评估了MMJ-CAR-2014-01研究(NCT01560663)中接受多西他赛-卡铂(TCb)治疗的TNBC患者的stil和TNBC- dx,或在NeoPACT试验(NCT03639948)中接受TCb+派姆单抗(TCb+Pem)治疗的TNBC患者。stil和TNBC-DX独立预测TCb+Pem治疗患者的pCR。stil≥30%且TNBC-DX pCR基因组评分高的患者,TCb+Pem的pCR率为91.3%。结合stil和TNBC-DX的综合分类确定了大约40%的NeoPACT队列,pCR率超过85%。综合分类是TCb+Pem治疗患者无事件生存的预后。整合stil和TNBC-DX可能促进化疗免疫治疗升级和降级试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信